Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Favorable-risk prostate cancer: Deferred and upfront surgery have similar outcomes

Key clinical point: Outcomes of deferred radical prostatectomy in favorable-risk patients with prostate cancer managed with active surveillance are similar to that of upfront surgery.

Major finding: The deferred vs up-front surgery groups had no difference in 5-year overall survival (98.1% vs 99.7%; P = .44), 5-year cancer-specific survival (100% vs 99.7%; P = .39) and 5-year biochemical-relapse-free survival (85.8% vs 82.4%; P = .38).

Study details: The data come from a retrospective study of 170 men with favorable-risk prostate cancer who underwent delayed radical prostatectomy for grade progression (grade group [GG] 2) after active surveillance and 405 matched patients with de novo GG 2 disease treated with up-front surgery.

Disclosures: No funding information was available. The authors declared no conflicts of interest.


Ahmad AE et al. J Urol. 2020 Sep 1. doi: 10.1097/JU.0000000000001070.